SG11201912195TA - Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies - Google Patents
Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathiesInfo
- Publication number
- SG11201912195TA SG11201912195TA SG11201912195TA SG11201912195TA SG11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA SG 11201912195T A SG11201912195T A SG 11201912195TA
- Authority
- SG
- Singapore
- Prior art keywords
- synucleinopathies
- formulations
- alpha
- treatment
- terminal end
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- 102000003802 alpha-Synuclein Human genes 0.000 title 1
- 108090000185 alpha-Synuclein Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762521287P | 2017-06-16 | 2017-06-16 | |
| PCT/US2018/037938 WO2018232369A1 (en) | 2017-06-16 | 2018-06-15 | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912195TA true SG11201912195TA (en) | 2020-01-30 |
Family
ID=64659951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912195TA SG11201912195TA (en) | 2017-06-16 | 2018-06-15 | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210138049A1 (enExample) |
| EP (1) | EP3638298A4 (enExample) |
| JP (3) | JP2021508672A (enExample) |
| KR (2) | KR20240150813A (enExample) |
| AU (2) | AU2018283510B8 (enExample) |
| BR (1) | BR112019026707A2 (enExample) |
| CA (1) | CA3067231A1 (enExample) |
| MX (1) | MX2019015286A (enExample) |
| SG (1) | SG11201912195TA (enExample) |
| WO (1) | WO2018232369A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
| SG11202003624SA (en) | 2017-10-27 | 2020-05-28 | United Neuroscience | Tau peptide immunogen constructs |
| SG11202107042WA (en) * | 2018-12-28 | 2021-07-29 | United Biomedical Inc | Peptide immunogens targeting interleukin 6 (il-6) and formulations thereof for immunotherapy of diseases impacted by il-6 dysregulation |
| AU2021276401A1 (en) | 2020-05-19 | 2022-12-15 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of Alzheimer's disease |
| JP2023536497A (ja) * | 2020-08-04 | 2023-08-25 | エイシー イミューン ソシエテ アノニム | 免疫原性化合物 |
| CN116783211A (zh) * | 2020-09-17 | 2023-09-19 | 普罗塞纳生物科学有限公司 | 治疗突触核蛋白病之α-突触核蛋白疫苗 |
| KR102505164B1 (ko) * | 2020-09-29 | 2023-02-28 | 서울대학교산학협력단 | 신경퇴행성 질환의 예방 또는 치료용 펩타이드 및 이를 포함하는 약학 조성물 |
| US20240270801A1 (en) * | 2021-06-18 | 2024-08-15 | Sumitomo Pharma Co., Ltd. | Epitope peptide of human alpha-synuclein and pharmaceutical composition including said peptide |
| EP4395894A4 (en) * | 2021-09-01 | 2025-08-06 | Vaxxinity Inc | METHODS FOR THE PREVENTION AND TREATMENT OF SYNUCLEINOPATHIES |
| MX2024010450A (es) | 2022-02-28 | 2024-09-18 | Tridem Bioscience Gmbh & Co Kg | Conjugado que consiste de o que comprende al menos un beta-glucano o un manano. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US20120142902A1 (en) * | 2007-02-23 | 2012-06-07 | The Regents Of The University Of California | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| PT2370466E (pt) * | 2008-12-19 | 2015-09-21 | Univ Zuerich | Autoanticorpos humanos anti-alfa-sinucleína |
| WO2013173827A2 (en) * | 2012-05-18 | 2013-11-21 | Board Of Regents Of The University Of Nebraska | Methods and compositions for inhibiting diseases of the central nervous system |
| WO2014031697A2 (en) * | 2012-08-21 | 2014-02-27 | The Institute Of Molecular Medicine | COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN |
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| US20170184612A1 (en) * | 2014-04-09 | 2017-06-29 | The Trustees Of Columbia University In The City Of New York | Use of leukocytes and novel biomarkers in the diagnosis, confirmation, and treatment of a neurological disorder |
| US10155030B2 (en) * | 2014-05-23 | 2018-12-18 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease |
-
2018
- 2018-06-15 BR BR112019026707-7A patent/BR112019026707A2/pt unknown
- 2018-06-15 WO PCT/US2018/037938 patent/WO2018232369A1/en not_active Ceased
- 2018-06-15 JP JP2020519016A patent/JP2021508672A/ja active Pending
- 2018-06-15 EP EP18816482.6A patent/EP3638298A4/en active Pending
- 2018-06-15 KR KR1020247032769A patent/KR20240150813A/ko active Pending
- 2018-06-15 SG SG11201912195TA patent/SG11201912195TA/en unknown
- 2018-06-15 CA CA3067231A patent/CA3067231A1/en active Pending
- 2018-06-15 AU AU2018283510A patent/AU2018283510B8/en active Active
- 2018-06-15 MX MX2019015286A patent/MX2019015286A/es unknown
- 2018-06-15 KR KR1020207001265A patent/KR20200054938A/ko not_active Ceased
- 2018-06-15 US US16/623,205 patent/US20210138049A1/en active Pending
-
2023
- 2023-03-15 JP JP2023040466A patent/JP7732676B2/ja active Active
-
2025
- 2025-02-28 JP JP2025032073A patent/JP2025090637A/ja active Pending
- 2025-09-26 AU AU2025238083A patent/AU2025238083A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112019026707A2 (pt) | 2020-06-30 |
| JP7732676B2 (ja) | 2025-09-02 |
| RU2020101121A3 (enExample) | 2021-10-15 |
| JP2025090637A (ja) | 2025-06-17 |
| EP3638298A4 (en) | 2021-05-05 |
| EP3638298A1 (en) | 2020-04-22 |
| AU2018283510B8 (en) | 2025-09-18 |
| KR20200054938A (ko) | 2020-05-20 |
| AU2018283510B2 (en) | 2025-06-26 |
| AU2018283510A1 (en) | 2020-01-16 |
| KR20240150813A (ko) | 2024-10-16 |
| JP2023082018A (ja) | 2023-06-13 |
| US20210138049A1 (en) | 2021-05-13 |
| JP2021508672A (ja) | 2021-03-11 |
| WO2018232369A1 (en) | 2018-12-20 |
| MX2019015286A (es) | 2020-08-17 |
| AU2025238083A1 (en) | 2025-10-23 |
| CA3067231A1 (en) | 2018-12-20 |
| RU2020101121A (ru) | 2021-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201912195TA (en) | Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies | |
| IL276464A (en) | Methods and preparations for administering therapeutic protein | |
| IL275777A (en) | Improved peptide drugs for the treatment of NASH and other disorders | |
| IL251462A0 (en) | Pharmaceutical formulations for oral administration of peptide or protein drugs | |
| HUE057083T2 (hu) | C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére | |
| ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
| EP3829597A4 (en) | TRIMER PEPTIDES FOR ANTISENSE ADMINISTRATION | |
| SG11202005526WA (en) | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis | |
| IL290520A (en) | Medicinal peptides | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| IL285144A (en) | Medicinal peptides | |
| SG11202104178TA (en) | Peptides and pharmaceutical compositions for treating eye diseases | |
| HUE059500T2 (hu) | Aminosavakat tartalmazó készítmények elhízás kezelésében történõ alkalmazásra | |
| IL281513A (en) | Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain | |
| EP3638204C0 (en) | TPX-100 PEPTIDE INTENDED TO REDUCE KNEE JOINT PAIN | |
| IL277734B1 (en) | Application of short peptides derived from PEDF in the treatment of osteoarthritis | |
| ZA201904386B (en) | S-arrestin peptides and therapeutic uses thereof | |
| ZA202100587B (en) | Peptide compounds and therapeutic uses of same | |
| IL282519A (en) | Peptide fragments for the treatment of diabetes | |
| PL3416677T3 (pl) | Kompozycja farmaceutyczna obejmująca rekombinowany hgh do leczenia niedoboru hormonu wzrostu | |
| IL275690A (en) | Nanoparticles for targeted delivery of therapeutic polypeptides | |
| EP3628048A4 (en) | PEPTIDES FOR CANCER TREATMENT | |
| ZA202100880B (en) | Short cyclic peptides for the treatment of graves' disease | |
| SG11202106847SA (en) | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions | |
| SG11202101945PA (en) | Peptide therapeutics for the treatment of cancer and uses thereof |